The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

被引:24
|
作者
Anonychuk, Andrea [1 ,2 ,3 ]
Woo, Gloria [4 ]
Vyse, Andrew [1 ]
Demarteau, Nadia [1 ]
Tricco, Andrea C. [5 ]
机构
[1] GlaxoSmithKline Vaccines, Wavre, Belgium
[2] Abbott Labs, Div Diagnost, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Div Diagnost, Mississauga, ON L5N 3R3, Canada
[4] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
关键词
NEISSERIA-MENINGITIDIS; CONJUGATE VACCINE; UNITED-STATES; SEROGROUP; IMMUNOGENICITY; POLYSACCHARIDE; SAFETY; W-135; INFECTION; ENGLAND;
D O I
10.1007/s40273-013-0057-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Invasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases. Objective To systematically review the literature on the costs and public health burden associated with IMD outbreaks. Methods Studies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community). Results Sixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222. Conclusion IMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
引用
收藏
页码:563 / 576
页数:14
相关论文
共 50 条
  • [21] Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
    Scholz, Stefan
    Schwarz, Magdalena
    Beck, Ekkehard
    Meszaros, Kinga
    Schneider, Melanie
    Ultsch, Bernhard
    Greiner, Wolfgang
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 367 - 387
  • [22] Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review
    Begum, Shahina
    Herrera-Restrepo, Oscar
    Rolland, Catherine
    Purushotham, Sneha
    Andani, Anar
    Shah, Hiral
    Kocaata, Zeki
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [23] Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis
    Purmohamad, Ali
    Abasi, Elham
    Azimi, Taher
    Hosseini, Sareh
    Safari, Hossein
    Nasiri, Mohammad Javad
    Fooladi, Abbas Ali Imani
    MICROBIAL PATHOGENESIS, 2019, 134
  • [24] The Burden of Pediatric Invasive Meningococcal Disease in Spain (2008-2013)
    Rivero-Calle, Irene
    Vilanova-Trillo, Lucia
    Pardo-Seco, Jacobo
    Blanco Salvado, Lidia
    Illade Quinteiro, Laura
    Martinon-Torres, Federico
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (04) : 407 - 413
  • [25] Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review
    Telisinghe, L.
    Waite, T. D.
    Gobin, M.
    Ronveaux, O.
    Fernandez, K.
    Stuart, J. M.
    Scholten, R. J. P. M.
    EPIDEMIOLOGY AND INFECTION, 2015, 143 (11) : 2259 - 2268
  • [26] Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature
    Guedes, Sandra
    Bertrand-Gerentes, Isabelle
    Evans, Keith
    Coste, Florence
    Oster, Philipp
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [27] Invasive meningococcal disease burden and prophylaxis: update on serogroup B vaccination
    Caceres, Rosario
    Guillen, Jaume
    Gonzalez-Inchausti, Carmen
    Gomez Sobrino, Mamen
    FARMACEUTICOS COMUNITARIOS, 2021, 13 (04): : 28 - 42
  • [28] Range of Clinical Manifestations Caused by Invasive Meningococcal Disease Due to Serogroup W: A Systematic Review
    Bertrand-Gerentes, Isabelle
    Fanchon, Laurent
    Coste, Florence
    Glover, Richard E.
    Guiddir, Tamazoust
    Taha, Muhamed-Kheir
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (10) : 2337 - 2351
  • [29] Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain
    Ivanova-Markova, Yoana
    Gonzalez-Dominguez, Almudena
    Hidalgo, Alvaro
    Sanchez, Raquel
    Garcia-Agua, Nuria
    Garcia-Ruiz, Antonio J.
    Amanda Vallejo-Aparicio, Laura
    Garcia, Andrea
    Rodriguez, Ruben
    de Gomensoro, Eduardo
    del Carmen Gonzalez-Inchausti, Maria
    Shen, Jing
    Begum, Najida
    Tafalla, Monica
    VACCINE, 2021, 39 (52) : 7646 - 7654
  • [30] Epidemiology and Clinical Burden of Meningococcal Disease in France: Scoping Review
    Baloche, Alexiane
    Dussart, Claude
    Bedouch, Pierrick
    Carrouel, Florence
    Mick, Gerard
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)